✦ LIBER ✦

A food and drug administration primer

✍ Scribed by Simon, Lee S.

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 61 KB
Volume: 55
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.21711

No coin nor oath required. For personal study only.

✦ Synopsis

4

* CFR ϭ Code of Federal Regulations; NDA ϭ New Drug Application.

📜 SIMILAR VOLUMES

Food and Drug Administration centennial:

Food and Drug Administration centennial: Recognizing the guardians of our drug supply

✍ John F. Beary 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB

Food and drug administration expanded ac

Food and drug administration expanded access to treatment : Implications for oncology patients

✍ Ralph S. Freedman; Maurie Markman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

On December 14, 2006, the FDA published simultaneously in the Federal Register their proposed rules amending regulations for expanded access to investigational drugs and for charging patients for investigational drugs. These proposed rules, if approved, could have important implications for patients

Food and drug administration low-level e

Food and drug administration low-level extremely-low-frequency magnetic field exposure facility

✍ Christopher C. Davis; Ian Barber; Mays L. Swicord 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

We describe the design, construction details, and performance characteristics of an exposure system designed to provide very well controlled extremely-low-frequency magnetic field exposures of in vitro samples. This system uses Helmholtz coils placed inside temperature-controlled m-metal chambers to

Overview of the 2006 Food and Drug Admin

Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis

✍ Tina L. Pinto Slottow; Ron Waksman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract Drug‐eluting stents (DES) seemed likely to mitigate the problem of restenosis and have become the predominant stent deployed during percutaneous coronary intervention (PCI). Sustained concerns about the rate of stent thrombosis (ST), particularly very late ST (>1 year following PCI) led

Tumor necrosis factor antagonist therapy

Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration

✍ S. Lori Brown; Mark H. Greene; Sharon K. Gershon; Evelyne T. Edwards; M. Miles B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## Objective Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymphoproliferative disorders in patie

The Food and Drug Law Institute (FDLI)

✍ J. Arcarese 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB